Business

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors

articleAddex Therapeutics LtdJune 18, 20253/company/addex-therapeutics-ltd/news/addex-therapeutics-to-release-q1-2025-financial-results-and-host-conference-call-on-june-19-2025
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

About this update from Addex Therapeutics Ltd

[{"type":"image","alt":"Addex Therapeutics","displaySize":"","headline":null,"caption":"Addex Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":231,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i1_J.LrQ5M.Eo1NBP2WLjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7","width":231,"height":115}},"lazy":false},{"type":"text","content":"Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.","length":584,"tagName":"p"},{"type":"text","content":"Title:   Addex Therapeutics Q1 2025 financial results and corporate update Date: June 19, 2025Time: 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT)","length":158,"tagName":"p"},{"type":"text","content":"Joining the Conference Call:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Participants are required to register in advance of the conference using the link provided below. Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.","length":210,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering. Participants may also use the call me feature instead of dialing the nearest dial in number.","length":267,"tagName":"p","attribs":{}}]}],"tagName":"ol","bulletedList":false,"length":477},{"type":"text","content":"Webcast registration URL: https://edge.media-server.com/mmc/p/esgoorze","length":70,"tagName":"p"},{"type":"text","content":"Conference call registration URL: https://register-conf.media-server.com...

More updates from Addex Therapeutics Ltd

biopharmaceutical companyneurological disordersTim Dyerallosteric modulatorsAddexdeveloping a portfolio